TLPH

Talphera Inc

• TipRanks·5d ago

  Talphera Earnings Call Highlights NEPHRO Trial Momentum

• NASDAQ·6d ago

  Talphera Reports Q1 Loss Of $2 Mln; Completes 50% Enrolment In Phase 3 Trial

• TipRanks·05/15 00:29

  Talphera Earnings Call Highlights Trial Momentum, Risks

• PUBT·05/14 12:01

  CorMedix Q1 net income rises to $38.6 million; revenue more than doubled to $127.4 million

• TipRanks·05/14 11:42

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• Seeking Alpha·05/13 23:21

  Talphera targets Niyad PMA filing in 2026 and potential approval in 2027 as NEPHRO enrollment surpasses 50%

• Benzinga·05/13 21:40

  Talphera Q1 2026 Earnings Call Transcript

• TipRanks·05/13 21:03

  Talphera reports Q1 EPS (4c) vs. (10c) last year

• Reuters·05/13 20:18

  Talphera Q1 net loss narrows as costs rise on higher development spending

• Benzinga·05/13 20:10

  Talphera Q1 EPS $(0.04) Beats $(0.07) Estimate, Sales $0.00 Down From $27.000K YoY

• Seeking Alpha·05/13 20:09

  Talphera GAAP EPS of -$0.04 beats by $0.04

• Seeking Alpha·05/13 14:00

  Here are the major earnings after the close Wednesday

• Benzinga·05/13 11:11

  Earnings Scheduled For May 13, 2026

• Dow Jones·04/30 18:40

  Talphera Price Target Announced at $3.00/Share by WestPark Capital

• Benzinga·04/30 18:33

  WestPark Capital Initiates Coverage On Talphera with Buy Rating, Announces Price Target of $3